Takeda Pharmaceutical Company Limited (NYSE:TAK) Shares Sold by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. cut its position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 3.0% during the 2nd quarter, Holdings Channel reports. The firm owned 1,483,493 shares of the company’s stock after selling 45,894 shares during the period. Envestnet Asset Management Inc.’s holdings in Takeda Pharmaceutical were worth $19,196,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of TAK. Rise Advisors LLC bought a new stake in shares of Takeda Pharmaceutical in the 1st quarter worth approximately $26,000. Principal Securities Inc. acquired a new position in shares of Takeda Pharmaceutical during the 4th quarter valued at about $28,000. GAMMA Investing LLC boosted its stake in Takeda Pharmaceutical by 50.9% during the 1st quarter. GAMMA Investing LLC now owns 2,864 shares of the company’s stock valued at $40,000 after purchasing an additional 966 shares during the period. Headlands Technologies LLC bought a new stake in Takeda Pharmaceutical during the 2nd quarter valued at approximately $59,000. Finally, Blue Trust Inc. lifted its position in shares of Takeda Pharmaceutical by 74.0% in the 2nd quarter. Blue Trust Inc. now owns 5,480 shares of the company’s stock worth $76,000 after acquiring an additional 2,330 shares during the period. Institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Price Performance

Shares of TAK stock opened at $14.91 on Tuesday. The stock has a 50 day moving average of $14.35 and a two-hundred day moving average of $13.75. The company has a current ratio of 1.26, a quick ratio of 0.74 and a debt-to-equity ratio of 0.65. Takeda Pharmaceutical Company Limited has a 12 month low of $12.57 and a 12 month high of $16.06. The company has a market capitalization of $47.19 billion, a P/E ratio of 27.11, a P/E/G ratio of 0.27 and a beta of 0.54.

Takeda Pharmaceutical (NYSE:TAK) last released its quarterly earnings results on Wednesday, July 31st. The company reported $0.56 earnings per share for the quarter, beating analysts’ consensus estimates of $0.37 by $0.19. The firm had revenue of $7.75 billion during the quarter. Takeda Pharmaceutical had a return on equity of 10.11% and a net margin of 6.02%. As a group, equities analysts expect that Takeda Pharmaceutical Company Limited will post 1.63 EPS for the current year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.